TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35244287

Group type: EXPERIMENTAL
Intervention: Recombinant follicle-stimulating hormone (rFSH) at doses of 0.5, 1.1, and 2.2 IU/kg/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recombinant follicle-stimulating hormone (rFSH) at all doses
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (ovulatory controls)
Number of subjects: 30
Study: 32267573

Group type: EXPERIMENTAL
Intervention: Vicagrel (24 mg loading dose, 6 mg maintenance dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading dose, 75 mg maintenance dose)
Number of subjects: 48
Study: 33538934

Group type: EXPERIMENTAL
Intervention: Video intervention adjuncts (VIAs) paired with dialectical behavior therapy (DBT) for IPV skills group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control condition (no VIAs)
Number of subjects: 24
Study: 33527139

Group type: EXPERIMENTAL
Intervention: Modified-Release Hydrocortisone (MR-HC)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standard glucocorticoid therapy
Number of subjects: 122
Study: 33539373

Group type: EXPERIMENTAL
Intervention: Public Opinion Survey of Human Attributes-Stuttering (POSHA-S)
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Income level (average to high)
Number of subjects: 650
Study: 33232866

Group type: COMPARATOR
Intervention: Footwear conditions (various types)
Number of subjects: 75
Study: 32105820

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2α (PGF2α) injection into the cervix before and after surgery
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2α (PGF2α) injection
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no PGF2α injection)
Number of subjects: 44
Study: 35157055

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE), 4 g/d
Number of subjects: 8179

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 8179
Study: 33733911

Group type: EXPERIMENTAL
Intervention: Stay Safe Link® (SSL)
Number of subjects: 472

Group type: COMPARATOR
Intervention: Stay Safe® (STS)
Number of subjects: 472
Study: 32176044

Group type: EXPERIMENTAL
Intervention: Evidence-based nursing (EBN) intervention
Number of subjects: 126

Group type: COMPARATOR
Intervention: Routine postoperative radiotherapy
Number of subjects: 126
Study: 35143628

Group type: EXPERIMENTAL
Intervention: Retrorectus mesh group (self-gripping prophylactic mesh)
Number of subjects: 244

Group type: COMPARATOR
Intervention: No mesh (control group)
Number of subjects: 244
Study: 33631356

Group type: EXPERIMENTAL
Intervention: Augmented Usual Care
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Collaborative Care
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Collaborative Care Plus
Number of subjects: 1200
Study: 35802375

Group type: EXPERIMENTAL
Intervention: 195-mg transdermal cannabidiol
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: 390-mg transdermal cannabidiol
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Cannabidiol (combined 195-mg and 390-mg)
Number of subjects: 188
Study: 34587373

Group type: EXPERIMENTAL
Intervention: Individualized BP-lowering treatment
Number of subjects: 242

Group type: COMPARATOR
Intervention: Standard BP-lowering treatment
Number of subjects: 242
Study: 33601858

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg once daily for 5 days along with general supportive treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard supportive treatment
Number of subjects: 200
Study: 34741703

Group type: EXPERIMENTAL
Intervention: SAAF substance use prevention program (7-session family skills training program)
Number of subjects: 252
Study: 32524129

Group type: EXPERIMENTAL
Intervention: Dynamic enteral and parenteral nutrition support with ω‐3 fish oil fat milk injection and glutamine
Number of subjects: 56

Group type: COMPARATOR
Intervention: Routine postoperative enteral and parenteral camp support
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Dynamic enteral and parenteral nutrition support
Number of subjects: 56
Study: 33031491

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) using Evolut or Evolut PRO valve
Number of subjects: 150
Study: 35584865

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (1.2 mg/kg), doxorubicin (25 mg/m2), vinblastine (6 mg/m2), dacarbazine (375 mg/m2), and rituximab (375 mg/m2) for four or six cycles.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin, rituximab, and risk-adapted chemotherapy.
Number of subjects: 30
Study: 34039403

Group type: EXPERIMENTAL
Intervention: Integrated model of radiomics and clinical features
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Radiomics model
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Clinical model
Number of subjects: 197
Study: 32400186

Group type: EXPERIMENTAL
Intervention: Solar Conduction Dryer (SCD)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 200
Study: 35950899

Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 1037

Group type: COMPARATOR
Intervention: Enzalutamide plus placebo
Number of subjects: 1037
Study: 34174191

Group type: EXPERIMENTAL
Intervention: Bivalent HPV vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 0
Study: 35926984

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolytics (urokinase median dose 250,000 IU, alteplase median dose 20 mg)
Number of subjects: 2263

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolytics
Number of subjects: 2263
Study: 32191400

Group type: EXPERIMENTAL
Intervention: UDCA 300 mg twice daily
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: UDCA 300 mg twice daily for 4 weeks followed by UDCA 300 mg twice daily and metformin 500 mg twice daily for 4 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vitamin E 400 IU twice daily
Number of subjects: 30
Study: 32442334

Group type: EXPERIMENTAL
Intervention: Physiotherapy consisting of electrotherapy and biofeedback, 3 days a week for 3 months
Number of subjects: 60
Study: 36205206

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (25,000 IU/d for 10 days)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard treatment (hydroxychloroquine)
Number of subjects: 182
Study: 34472926

Group type: EXPERIMENTAL
Intervention: Effective communication
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Externalizing behavior problems
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Observed parenting behaviors
Number of subjects: 117
Study: 32546269

Group type: EXPERIMENTAL
Intervention: Short-course antibiotic therapy for 2 weeks
Number of subjects: 298

Group type: COMPARATOR
Intervention: Conventional antibiotic therapy (4-6 weeks)
Number of subjects: 298
Study: 35871815

Group type: EXPERIMENTAL
Intervention: Single intramuscular glucocorticoid injection (120 mg) and a 1‐year course of oral methotrexate (up to 25 mg/week)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo (single injection and tablets for 1 year)
Number of subjects: 236
Study: 35604466

Group type: EXPERIMENTAL
Intervention: Directed rhythmic-melodic voice training (SIPARI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Language therapy (control group)
Number of subjects: 20
Study: 35984159

Group type: COMPARATOR
Intervention: Empirical concomitant therapy (CoT): rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, and metronidazole 500 mg twice daily for 14 days
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Tailored therapy (TaT): rabeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg twice daily for 14 days for point mutation-negative patients; rabeprazole 20 mg twice daily, metronidazole 500 mg thrice daily, bismuth 120 mg, and tetracycline 500 mg 4 times daily for 14 days for point mutation-positive patients
Number of subjects: 290

Group type: COMPARATOR
Intervention: Empirical concomitant therapy (CoT) in point mutation-positive patients
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Tailored therapy (TaT) in point mutation-positive patients
Number of subjects: 290
Study: 35510343

Group type: EXPERIMENTAL
Intervention: Oral health promotion intervention (individual support to improve oral health)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 263
Study: 33416422

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 285

Group type: COMPARATOR
Intervention: Type 2 diabetes
Number of subjects: 285
Study: 35835650

Group type: EXPERIMENTAL
Intervention: HP-Guar nanoemulsion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 20
Study: 34541982

Group type: EXPERIMENTAL
Intervention: PRIME needle-free injection system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard needle and syringe
Number of subjects: 0
Study: 35809825

Group type: EXPERIMENTAL
Intervention: Information on herd immunity (> 80% of the entire population must be vaccinated)
Number of subjects: 4288

Group type: COMPARATOR
Intervention: Information on herd immunity (no information)
Number of subjects: 4288

Group type: EXPERIMENTAL
Intervention: Vaccine with 90% efficacy
Number of subjects: 4288

Group type: EXPERIMENTAL
Intervention: Risk of adverse reactions to be 1 over 10 in 10,000
Number of subjects: 4288

Group type: EXPERIMENTAL
Intervention: Knowledge on herd immunity target
Number of subjects: 4288
Study: 33684506

Group type: EXPERIMENTAL
Intervention: sucrose (80 g/day)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: fructose (80 g/day)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: glucose (80 g/day)
Number of subjects: 94

Group type: COMPARATOR
Intervention: control group (SSB abstinence)
Number of subjects: 94
Study: 35345950

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Usual care (CG)
Number of subjects: 76
Study: 33493346

Group type: EXPERIMENTAL
Intervention: Clinical malaria episodes
Number of subjects: 0
Study: 32688041

Group type: EXPERIMENTAL
Intervention: Direct decompression with wide posterior decompression and operative stabilization
Number of subjects: 46

Group type: COMPARATOR
Intervention: Indirect decompression through ligamentotaxis
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Direct decompression
Number of subjects: 46
Study: 35457787

Group type: EXPERIMENTAL
Intervention: Remote PA follow-up intervention after face-to-face program
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BCI4 group (four behavior change coaching interviews)
Number of subjects: 30

Group type: COMPARATOR
Intervention: BCI3 group (three behavior change coaching interviews)
Number of subjects: 30
Study: 34059572

Group type: EXPERIMENTAL
Intervention: High-quality care (n=58)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Routine care (n=58)
Number of subjects: 116
Study: 32353056

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) measured using ActiGraph accelerometers
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) outdoors
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Adult-managed time
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) at all intensity levels
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Physical activity (PA)
Number of subjects: 42
Study: 35302945

Group type: EXPERIMENTAL
Intervention: SMS text messaging reminder
Number of subjects: 591

Group type: COMPARATOR
Intervention: Email reminder
Number of subjects: 591
Study: 35932209

Group type: EXPERIMENTAL
Intervention: T-piece Resuscitators (TPR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 0
Study: 33411915

Group type: EXPERIMENTAL
Intervention: Parental Depression (PD)
Number of subjects: 200
Study: 32080148

Group type: EXPERIMENTAL
Intervention: traditional treatment + intravenous infusion of edaravone 30 mg twice a day for 14 days
Number of subjects: 112
Study: 34402135

Group type: COMPARATOR
Intervention: NOAC
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: LAAC
Number of subjects: 144
Study: 35255966

Group type: EXPERIMENTAL
Intervention: MenSC-derived secretome treatment (5 mL intravenous infusions for five days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (placebo, 5 mL intravenous infusions for five days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenSC-derived secretome treatment
Number of subjects: 0
Study: 33245674

Group type: EXPERIMENTAL
Intervention: Piezo surgery
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Laser surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lindeman bur
Number of subjects: 60

Group type: COMPARATOR
Intervention: Steel bur
Number of subjects: 60

Group type: COMPARATOR
Intervention: Tungsten carbide bur
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diamond bur
Number of subjects: 60
Study: 32138746

Group type: EXPERIMENTAL
Intervention: Simvastatin plus fenofibrate
Number of subjects: 853

Group type: COMPARATOR
Intervention: Simvastatin plus placebo
Number of subjects: 853
Study: 35839158

Group type: EXPERIMENTAL
Intervention: Human amniotic membrane (HAM)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Bovine collagen
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 43
Study: 34304029

Group type: EXPERIMENTAL
Intervention: Adapted ASSIP intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Treatment as usual control
Number of subjects: 34
Study: 34837169

Group type: EXPERIMENTAL
Intervention: Palbociclib test formulation (125 mg) under fasting condition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Palbociclib test formulation (125 mg) under fed condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Palbociclib reference formulation (125 mg) under fasting condition
Number of subjects: 60

Group type: COMPARATOR
Intervention: Palbociclib reference formulation (125 mg) under fed condition
Number of subjects: 60
Study: 32144056

Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 60
Study: 35866804

Group type: EXPERIMENTAL
Intervention: Biosis SIS
Number of subjects: 186

Group type: COMPARATOR
Intervention: Control SIS (commercial)
Number of subjects: 186
Study: 34397802

Group type: EXPERIMENTAL
Intervention: Lumboperitoneal shunt (LPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt (VPS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LPS and VPS
Number of subjects: 0
Study: 32808029

Group type: EXPERIMENTAL
Intervention: L-cysteine (1200 mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: L-cysteine (600 mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 35895764

Group type: EXPERIMENTAL
Intervention: BUP-DEX (bupivacaine mixed with dexmedetomidine)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BLS (bupivacaine liposomal suspension)
Number of subjects: 26

Group type: COMPARATOR
Intervention: CTRL (no TAP block)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: BUP-DEX and BLS
Number of subjects: 26
Study: 33785271

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) or biliopancreatic diversion with duodenal switch (BPD/DS)
Number of subjects: 18
Study: 32357152

Group type: EXPERIMENTAL
Intervention: Hypnosis group (n = 136)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Relaxation group (n = 134)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Usual care group (n = 79)
Number of subjects: 349
Study: 35468330

Group type: EXPERIMENTAL
Intervention: Contralateral BPTB graft
Number of subjects: 88

Group type: COMPARATOR
Intervention: Ipsilateral BPTB graft
Number of subjects: 88
Study: 32789530

Group type: EXPERIMENTAL
Intervention: Bag-of-features (BOF) features with augmentation from contrast-enhanced MRI (CE-MRI)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Radiomic analysis with pre-contrast MRI
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Analysis with CE-MRI
Number of subjects: 56
Study: 34736546

Group type: EXPERIMENTAL
Intervention: S‐AII (self-affirmation intervention)
Number of subjects: 175

Group type: COMPARATOR
Intervention: N‐AII (non-affirming implementation intentions)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control (mere goal intention condition)
Number of subjects: 175
Study: 33318849

Group type: EXPERIMENTAL
Intervention: CBL combined with STEM education concept
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional education programme
Number of subjects: 0
Study: 32493383

Group type: EXPERIMENTAL
Intervention: Modified Diagnostic Strategy (MODS) with D-dimer threshold raised to 1000 ng/ml if no items of the YEARS score are present.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care with D-dimer threshold of 500 ng/ml for patients aged 50 years or younger and age × 10 for older patients.
Number of subjects: 0
Study: 35293783

Group type: EXPERIMENTAL
Intervention: Erythromycin 400 mg twice daily for 4 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Azithromycin 125 mg twice daily for 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 35308438

Group type: EXPERIMENTAL
Intervention: Audiovisual distraction (AVD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mute-video distraction (MVD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control technique
Number of subjects: 60
Study: 32061387

Group type: EXPERIMENTAL
Intervention: Early measles vaccination (MV) at 4.5 + 9 months
Number of subjects: 3548

Group type: COMPARATOR
Intervention: Control group (MV at 9 months)
Number of subjects: 3548
Study: 32910863

Group type: EXPERIMENTAL
Intervention: Cytoflavin antioxidant energy therapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard conservative therapy
Number of subjects: 151
Study: 34859519

Group type: EXPERIMENTAL
Intervention: Telephone monitoring and counseling (TMC; n = 59)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Addiction comprehensive health enhancement support system (ACHESS; n = 68)
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Telephone monitoring and counseling + ACHESS (TMC + ACHESS; n = 70)
Number of subjects: 262

Group type: COMPARATOR
Intervention: IOP only (TAU; n = 65)
Number of subjects: 262
Study: 33789267

Group type: EXPERIMENTAL
Intervention: Intratympanic triamcinolone acetonide injections (up to 3 injections at 1-week intervals)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Intratympanic triamcinolone acetonide injections
Number of subjects: 152
Study: 32646010

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with a low-carbohydrate formula diet (INT)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Lifestyle intervention only (CON)
Number of subjects: 141
Study: 35686351

Group type: EXPERIMENTAL
Intervention: Auditory stimulation in-phase with slow oscillations
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham condition without auditory stimuli
Number of subjects: 18
Study: 34192419

Group type: EXPERIMENTAL
Intervention: BAY 2433334 (5–150 mg as oral solution or immediate-release tablets)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: BAY 2433334 (5 mg tablets) with a high-calorie breakfast
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: BAY 2433334
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 36331590

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS) and posterior nasal neurectomy (PNN)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 46
Study: 34351722

Group type: EXPERIMENTAL
Intervention: Therapeutic-dose anticoagulation with heparin
Number of subjects: 1098

Group type: COMPARATOR
Intervention: Usual-care thromboprophylaxis
Number of subjects: 1098
Study: 32971450

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU/week)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (500 μg/day)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Both vitamin D3 and chromium picolinate
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 35748058

Group type: EXPERIMENTAL
Intervention: YH4808 at 30, 50, 100, 200, 400, 600, and 800 mg (single oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YH4808 at 100, 200, and 400 mg (multiple once-daily oral doses for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Omeprazole at 40 mg (active comparator)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YH4808 (repeated doses)
Number of subjects: 0
Study: 34182800

Group type: EXPERIMENTAL
Intervention: Protocol A (institution's radial band deflation protocol)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Protocol B (Cohen and Alfonso's radial band deflation protocol)
Number of subjects: 100
Study: 32212297

Group type: EXPERIMENTAL
Intervention: Patients with 4+ comorbidities
Number of subjects: 6945

Group type: EXPERIMENTAL
Intervention: Higher comorbidity burden
Number of subjects: 6945
Study: 35380933

Group type: EXPERIMENTAL
Intervention: Trending norm messages
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 156
Study: 35983099

Group type: EXPERIMENTAL
Intervention: POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin)
Number of subjects: 230

Group type: COMPARATOR
Intervention: SOX/CAPOX/FOLFOX
Number of subjects: 230
Study: 32285530

Group type: EXPERIMENTAL
Intervention: Active commuting intervention (exact details not specified)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (exact details not specified)
Number of subjects: 73
Study: 34978680

Group type: EXPERIMENTAL
Intervention: Calorie Information
Number of subjects: 283

Group type: COMPARATOR
Intervention: No Calorie Information
Number of subjects: 283
Study: 33568018

Group type: EXPERIMENTAL
Intervention: habit‐forming exercise, home safety, and community mobility training
Number of subjects: 370

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 370
Study: 32371537

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with trastuzumab-containing regimens
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 130
Study: 34411904

Group type: EXPERIMENTAL
Intervention: Expert advice about therapeutic exercise
Number of subjects: 500

Group type: COMPARATOR
Intervention: Normal lifestyle habits (Control)
Number of subjects: 500
Study: 33244571

Group type: EXPERIMENTAL
Intervention: SARC-F screening
Number of subjects: 122
Study: 33728848

Group type: EXPERIMENTAL
Intervention: ipidacrine added to traditional therapy (n=50)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional therapy (n=42)
Number of subjects: 92